{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-057883","form_type":"8-K","ticker":"CTOR","cik":"0001851484","company_name":"CITIUS ONCOLOGY, INC.","filed_at":"2026-05-15T20:44:23+00:00","discovered_at":"2026-05-15T20:45:01.423505+00:00","generated_at":"2026-05-15T21:02:24.715352+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Citius Oncology reports Q2 FY2026 net loss $26.6M; LYMPHIR revenue $1.7M, launch progressing","bullets":["Net product revenues $1.7M in Q2 ($5.6M H1) vs $0 prior year; gross margin 80%.","Net loss $26.6M vs $7.7M prior year, driven by $19.7M one-time CMO contract cancellation.","Cash $2.6M at March 31; subsequent $11.5M warrant exercise and $10M debt tranche from Avenue Capital ($25M facility).","83% of target accounts on formulary or in review; near 100% payer coverage; initial European shipment.","Hired Jefferies as exclusive financial advisor to evaluate strategic alternatives; combined cash runway through Nov 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-057883","json":"https://secwatch.observer/filing/0001213900-26-057883.json","markdown":"https://secwatch.observer/filing/0001213900-26-057883.md","text":"https://secwatch.observer/filing/0001213900-26-057883.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1851484/000121390026057883/0001213900-26-057883-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1851484/000121390026057883/ea0291035-8k_citius.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T21:02:24.715352+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e10e35fcdd2fb6617c09f4ecaea53253728d363c","claim":"CITIUS ONCOLOGY, INC. reported the fiscal second quarter ended March 31, 2026 results: revenue $1.7 million.","evidence_excerpt":"revenue milestones; and, ○ approximately $11.5 million in gross proceeds received May 5, 2026 from the exercise of certain outstanding warrants; and, ● Net product revenues of $1.7 million for the three months ended March 31, 2026, compared to no revenue for the three months ended March 31, 2025; and $5.6 million for the six months ended March 31, 2026, compared","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1851484/000121390026057883/0001213900-26-057883-index.htm","confidence":0.85,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal second quarter ended March 31, 2026"},{"label":"Revenue","value":"$1.7 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}